Trials / Completed
CompletedNCT00202774
Safety and Efficacy Study of XELOX vs. Oxaliplatin+5-FU CI as First Line Treatment in Metastatic Colorectal Cancer
Phase III, Multicenter, Ramdomised, Open-label, Study to Evaluate the Safety and Efficacy of Combination Therapy With XELOX vs. Oxaliplatin and 5-FU CI as First Line Treatment in Advanced or Metastatic Colorectal Cancer
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 348 (actual)
- Sponsor
- Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine time to disease progression of combination therapy with capecitabine and oxaliplatin (XELOX) vs. oxaliplatin and 5-fluorouracil in continous infusion (5-FU CI) as first line treatment in advanced or metastatic colorectal cancer
Detailed description
The purpose of this study is to determine time to disease progression of combination therapy with capecitabine and oxaliplatin (XELOX) vs. oxaliplatin and 5-fluorouracil in continous infusion (5-FU CI) as first line treatment in advanced or metastatic colorectal cancer
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | (capecitabine, oxaliplatin, 5-fluorouracil) |
Timeline
- Start date
- 2002-04-01
- Primary completion
- 2004-08-01
- Completion
- 2005-12-01
- First posted
- 2005-09-20
- Last updated
- 2023-04-12
Locations
1 site across 1 country: Spain
Source: ClinicalTrials.gov record NCT00202774. Inclusion in this directory is not an endorsement.